Cover ImageSALE
市場調查報告書

溶小體儲積症的全球市場:2017年∼2021年

Global Lysosomal Storage Diseases Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310019
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
溶小體儲積症的全球市場:2017年∼2021年 Global Lysosomal Storage Diseases Market 2017-2021
出版日期: 2017年09月18日 內容資訊: 英文 104 Pages
簡介

全球溶小體儲積症市場,預計從2017年到2021年,7.43%的CAGR(年複合成長率)擴大。

本報告提供全球溶小體儲積症市場現狀與今後的預測,各藥物類別、各地區的趨勢,市場的發展因素與課題,主要的供應商的簡介等。

第1章 摘要整理

第2章 調查範圍

第3章 市場調查手法

第4章 簡介

  • 市場趨勢的概要

第5章 溶小體儲積症(LSD)的理解

  • 簡介

第6章 開發平台

第7章 市場形勢

  • 市場概要
  • 波特的五力分析
  • 市場規模、預測
  • 溶小體儲積症治療的最初的認證藥
  • 市場概要
  • 主要的產品

第8章 市場區隔:各治療法

  • 酵素補充療法(ERT)
  • 基材還原療法(SRT)
  • 胱胺酸乾涸劑

第9章 地區區分

  • 各地區的市場區隔
  • 歐洲、中東、非洲
  • 南北美洲
  • 亞太地區

第10章 決策結構

第11章 市場成長因素與課題

第12章 市場趨勢

第13章 業者情勢

  • 競爭模式

第14章 主要供應商分析

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire
  • 其他有潛力的供應商

第15章 附錄

  • 簡稱清單

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR14696

About Lysosomal Storage Diseases

Lysosomal storage diseases (LSDs) refer to a group of diseases arising because of the deficiency of lysosomal enzymes, which leads to the accumulation of partially digested or undigested macromolecules inside the cell. LSDs includes progressive diseases with variable ages of onset and clinical symptoms. LSDs are autosomal recessive disorders that are passed on from generation to generation. However, Fabry disease and MPS II are X-linked recessive disorders, which are inherited through mutated alleles on X chromosome.

Technavio's analysts forecast the global lysosomal storage diseases market to grow at a CAGR of 7.43% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lysosomal storage diseases market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Lysosomal Storage Diseases Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire

Other Prominent Vendors

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Chiesi Farmaceutici
  • Greenovation Biotech and FGK Clinical Research
  • Horizon Pharma
  • Leadiant Biosciences
  • Mylan
  • Pfizer
  • Protalix
  • Raptor
  • Recordati
  • Synageva BioPharma
  • Valerion Therapeutics
  • Vtesse

Market driver

  • Unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Expensive treatment regimen for LSDs
  • For a full, detailed list, view our report

Market trend

  • Regulatory assistance in emerging nations
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research methodology

PART 04: Introduction

  • Market outline

PART 05: Understanding LSDs

  • Introduction

PART 06: Pipeline

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by therapy

  • Enzyme replacement therapy (ERT)
  • Substrate reduction therapy (SRT)
  • Cystine depleting agents

PART 09: Market segmentation by geography

  • Geographical segmentation
  • LSDs market in EMEA
  • LSDs market in Americas
  • LSDs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Trends

  • Advent of modern technologies
  • Regulatory assistance in emerging nations
  • Increased R&D activities
  • Increased focus on gene therapy
  • Emergence of immunotherapy
  • Growing public awareness

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire
  • Other Prominent Vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Classification of LSDs
  • Exhibit 02: Pipeline snapshot
  • Exhibit 03: Pipeline landscape based on various LSDs
  • Exhibit 04: Key clinical trials
  • Exhibit 05: Global LSDs market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis of the global LSDs market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Global LSDs market segmentation by therapy
  • Exhibit 09: Global LSDs market share by therapy 2016
  • Exhibit 10: Global LSDs ERT market 2016-2021 ($ millions)
  • Exhibit 11: Potential benefits of using ERT for the treatment of various LSDs
  • Exhibit 12: Global LSDs SRT market 2016-2021 ($ millions)
  • Exhibit 13: Global LSDs cystine depleting agents market 2016-2021 ($ millions)
  • Exhibit 14: Global LSDs market share by geography 2016 and 2021
  • Exhibit 15: Global LSDs market revenue by geography 2016-2021
  • Exhibit 16: Global LSDs market share by geography 2016-2021
  • Exhibit 17: Market scenario in EMEA
  • Exhibit 18: LSDs market in EMEA 2016-2021 ($ millions)
  • Exhibit 19: Incentives provided for orphan drugs by EU regulation
  • Exhibit 20: Market scenario in Americas
  • Exhibit 21: LSDs market in Americas 2016-2021 ($ millions)
  • Exhibit 22: Orphan drug development and regulatory challenges
  • Exhibit 23: Incentives provided for orphan drugs by US regulation
  • Exhibit 24: LSDs market in APAC 2016-2021 ($ millions)
  • Exhibit 25: Incentives provided for orphan drugs by Japanese regulation
  • Exhibit 26: Incentives provided for orphan drugs by Australian regulation
  • Exhibit 27: ICD-10 coverage for some of the LSDs
  • Exhibit 28: US FDA filed to approved time: Orphan drugs versus non-orphan drugs and others (median time in months)
  • Exhibit 29: Usefulness of DNA-based testing
  • Exhibit 30: Competitive structure analysis of global LSDs market 2016
  • Exhibit 31: Actelion Pharmaceuticals: Key highlights
  • Exhibit 32: Actelion Pharmaceuticals: Strength assessment
  • Exhibit 33: Actelion Pharmaceuticals: Strategy assessment
  • Exhibit 34: Actelion Pharmaceuticals: Opportunity assessment
  • Exhibit 35: BioMarin: Key highlights
  • Exhibit 36: BioMarin: Strength assessment
  • Exhibit 37: BioMarin: Strategy assessment
  • Exhibit 38: BioMarin Pharmaceuticals: Opportunity assessment
  • Exhibit 39: Genzyme: Key highlights
  • Exhibit 40: Genzyme: Strength assessment
  • Exhibit 41: Genzyme: Strategy assessment
  • Exhibit 42: Genzyme: Opportunity assessment
  • Exhibit 43: Shire: Key highlights
  • Exhibit 44: Shire: Strength assessment
  • Exhibit 45: Shire: Strategy assessment
  • Exhibit 46: Shire: Opportunity assessment
Back to Top